Rejigging The Benefit-Risk Balance For Advanced Therapies In The EU
Executive Summary
The European Medicines Agency’s Committee for Advanced Therapies has revealed its priorities for addressing the challenges manufacturers face in the fast-growing field of advanced therapies.